Surgical resection after TNFerade™ therapy for locally advanced pancreatic cancer

Manprett K. Chadha, Alan Litwin, Charles Levea, Renuka Iyer, Gary Yang, Milind Javle, John F. Gibbs

Research output: Contribution to journalArticle

8 Scopus citations


Context: Treatment of pancreatic cancer remains a major oncological challenge and survival is dismal. Most patients, present with advanced disease at diagnosis and are not candidates for curative resection. Preoperative chemoradiation may downstage and improve survival in locally advanced pancreatic cancer. This has prompted investigators to look for novel neoadjuvant therapies. Gene therapy for pancreatic cancer is a novel investigational approach that may have promise. TNFerade™ is a replication deficient adenovirus vector carrying the human tumor necrosis factor (TNF)-alpha gene regulated under control of a radiation-inducible gene promoter. Transfection of tumor cells with TNFerade™ maximizes the antitumor effect of TNF-alpha under influence of radiation leading to synergistic effects in preclinical studies. Case report: We describe a case of locally advanced unresectable pancreatic cancer treated with a novel multimodal approach utilizing gene therapy with TNFerade™ and concurrent chemoradiation that was followed by successful surgical resection. Conclusion: Neoadjuvant TNFerade™ based chemoradiation therapy may be a useful adjunct to treatment of locally advanced pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)535-538
Number of pages4
JournalJournal of the Pancreas
Issue number5
Publication statusPublished - Sep 25 2009


All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Chadha, M. K., Litwin, A., Levea, C., Iyer, R., Yang, G., Javle, M., & Gibbs, J. F. (2009). Surgical resection after TNFerade™ therapy for locally advanced pancreatic cancer. Journal of the Pancreas, 10(5), 535-538.